Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maurice G V M Russel"'
Autor:
Sinan Guloksuz, Marieke Wichers, Gunter Kenis, Maurice G V M Russel, Annick Wauters, Robert Verkerk, Baer Arts, Jim van Os
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e60435 (2013)
Crohn's disease (CD) is associated with immune activation and depressive symptoms. This study determines the impact of anti-tumor necrosis factor (TNF)-α treatment in CD patients on depressive symptoms and the degree to which tryptophan (TRP) availa
Externí odkaz:
https://doaj.org/article/f0d2c259e28447f98ec46b782cb3e308
Autor:
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch
Publikováno v:
Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716
https://repository.ubn.ru.nl/handle/2066/293716
Autor:
Femke Crouwel, Melek Simsek, Marjon A de Boer, Chris J J Mulder, Emma M van Andel, Rob H Creemers, Dirk P van Asseldonk, Ad A van Bodegraven, Carmen S Horjus, Marijn C Visschedijk, Angelique L M Weusthuis, Margien L Seinen, Bindia Jharap, Fiona D M van Schaik, Ishfaq Ahmad, Paul J Boekema, Greetje J Tack, Louktje Wormmeester, Maurice W M D Lutgens, Petra G A van Boeckel, Lennard P L Gilissen, Marjon Kerkhof, Maurice G V M Russel, Frank Hoentjen, Maartje E Bartelink, Johan P Kuijvenhoven, Jeroen W J Maljaars, Willemijn A van Dop, Janneke Wonders, Michael M P J A van der Voorn, Hans J C Buiter, Nanne K de Boer
Publikováno v:
Journal of Crohn's & colitis, 17(5), 738-745. Elsevier
Journal of Crohn's and Colitis. OXFORD UNIV PRESS
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 17, 738-745
Crouwel, F, Simsek, M, de Boer, M A, Mulder, C J J, van Andel, E M, Creemers, R H, van Asseldonk, D P, van Bodegraven, A A, Horjus, C S, Visschedijk, M C, Weusthuis, A L M, Seinen, M L, Jharap, B, van Schaik, F D M, Ahmad, I, Boekema, P J, Tack, G J, Wormmeester, L, Lutgens, M W M D, van Boeckel, P G A, Gilissen, L P L, Kerkhof, M, Russel, M G V M, Hoentjen, F, Bartelink, M E, Kuijvenhoven, J P, Maljaars, J W J, van Dop, W A, Wonders, J, van der Voorn, M M P J A, Buiter, H J C & de Boer, N K 2023, ' Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease ', Journal of Crohn's & colitis, vol. 17, no. 5, pp. 738-745 . https://doi.org/10.1093/ecco-jcc/jjac183, https://doi.org/10.1093/ecco-jcc/jjac183
Journal of Crohn's and Colitis, 17, 5, pp. 738-745
Journal of Crohn's and Colitis. OXFORD UNIV PRESS
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 17, 738-745
Crouwel, F, Simsek, M, de Boer, M A, Mulder, C J J, van Andel, E M, Creemers, R H, van Asseldonk, D P, van Bodegraven, A A, Horjus, C S, Visschedijk, M C, Weusthuis, A L M, Seinen, M L, Jharap, B, van Schaik, F D M, Ahmad, I, Boekema, P J, Tack, G J, Wormmeester, L, Lutgens, M W M D, van Boeckel, P G A, Gilissen, L P L, Kerkhof, M, Russel, M G V M, Hoentjen, F, Bartelink, M E, Kuijvenhoven, J P, Maljaars, J W J, van Dop, W A, Wonders, J, van der Voorn, M M P J A, Buiter, H J C & de Boer, N K 2023, ' Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease ', Journal of Crohn's & colitis, vol. 17, no. 5, pp. 738-745 . https://doi.org/10.1093/ecco-jcc/jjac183, https://doi.org/10.1093/ecco-jcc/jjac183
Journal of Crohn's and Colitis, 17, 5, pp. 738-745
Background Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth. Methods In this multicentre case series, IBD pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5eec57469089c4cf6a4da189d0a517
https://hdl.handle.net/1887/3593862
https://hdl.handle.net/1887/3593862
Autor:
Pepijn W A, Thomas, Lisa J T, Smits, Maarten, Te Groen, Rachel L, West, Maurice G V M, Russel, Jeroen M, Jansen, Tessa E H, Römkens, Frank, Hoentjen
Publikováno v:
European Journal of Gastroenterology & Hepatology, 34, 5, pp. 488-495
European Journal of Gastroenterology & Hepatology, 34, 488-495
European Journal of Gastroenterology & Hepatology, 34, 488-495
Limited data are available on biological therapy de-escalation after prior escalation in inflammatory bowel disease (IBD) patients. This study aimed to assess the frequency and success rate of de-escalation of biological therapy in IBD patients after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192a4656261c4ec5823ed3babe5a4edf
Autor:
Pepijn W A Thomas, Nathan den Broeder, Monique Derikx, Wietske Kievit, Rachel L West, Maurice G V M Russel, Jeroen M Jansen, Tessa E H Römkens, Frank Hoentjen
Publikováno v:
Inflammatory Bowel Diseases, 28, 1813-1820
Inflammatory Bowel Diseases, 28, 12, pp. 1813-1820
Inflammatory Bowel Diseases, 28, 12, pp. 1813-1820
Background There are limited real-world data on the change in total work impairment (TWI) in biological-treated patients with inflammatory bowel disease (IBD). This study aimed to evaluate the real-world effects of initiating biological therapy or to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd6585f177fa7cc5f5d5a9f7fa38a7c
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/287916
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/287916
Autor:
Cor G. M. I. Baeten, Regina G. H. Beets-Tan, Stephan J. van der Hagen, Wim G. van Gemert, Peter B. Soeters, Maurice G. V. M. Russel
Publikováno v:
Diseases of the Colon & Rectum, 48(4), 758-767. LIPPINCOTT WILLIAMS & WILKINS
PURPOSE: This study was designed to assess the healing rate of complex perianal fistulas in Crohn's disease after a multistep strategy, including induction treatment with Infliximab in case of active proctitis, followed by definitive surgery. METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c268d7c7bc61d4b5f1e361eed0db532
https://cris.maastrichtuniversity.nl/en/publications/46169bd3-975f-4bc5-ae00-8e8f106af375
https://cris.maastrichtuniversity.nl/en/publications/46169bd3-975f-4bc5-ae00-8e8f106af375
Autor:
Jan G M C, Damoiseaux, Bas, Bouten, Annick M L W, Linders, Jos, Austen, Caroline, Roozendaal, Maurice G V M, Russel, Pierre-Philippe, Forget, Jan Willem Cohen, Tervaert
Publikováno v:
Journal of clinical immunology. 22(5)
Both celiac disease and inflammatory bowel disease (IBD) are characterized by chronic diarrhea and the presence of distinct (auto)antibodies. In the present study we wanted to determine the prevalence of serological markers for inflammatory bowel dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ff602e618e0a59455589b6340fbebb3
https://pubmed.ncbi.nlm.nih.gov/12405161
https://pubmed.ncbi.nlm.nih.gov/12405161